Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

Caitlin E. Cox

February 26, 2025

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

Better Clopidogrel Response Seen with Increased Smoking Levels

Jason Kahn

March 21, 2012

Advertisement

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

Semaglutide Has Similar Benefits in Women and Men With HFpEF

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

Better Clopidogrel Response Seen with Increased Smoking Levels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content